Wikipedia

Thomas Oxley (neurologist)

Thomas J. Oxley is the chief executive officer of Synchron and neurointerventionist at Mount Sinai Hospital in New York City.[1] Trained as a vascular and interventional neurologist, he established the Vascular Bionics laboratory at the University of Melbourne and is currently co-head of this lab.[2] Oxley is best known for founding Synchron, a company building next-generation brain computer interface solutions that has recently announced the first clinical data on a novel stent electrode (Stentrode) neural interface that is inserted through blood vessels. The company was initiated sometime after his cold-call to DARPA for funding, and has received substantial funding from the U.S. Defense Advanced Research Projects Agency (DARPA) and the Australian government to research this minimally-invasive neural interface technology.[3]

Thomas Oxley
Dr. Thomas Oxley
Born
Canberra, Australia
EducationMonash University, MD
University of Melbourne,
PhD Neural Engineering
Years active2012-Present
Known forInterventional Neurologist
CEO, Synchron, Inc.
Medical career
ProfessionNeurointerventionalist, CEO
FieldNeurology
InstitutionsSynchron, Inc., University of Melbourne
Websitesynchron.com

Work in brain-computer interface

edit

While Oxley has been conducting research in motor systems since 2003, he is said to have conceived the idea for the Stentrode™ in 2007 and he led the original team at the University of Melbourne that created the technology. Stentrode is the first motor neuroprosthesis, a form of brain-computer interface implanted via the patient's blood vessels. Oxley's team in Australia was the only non-US-based group funded by DARPA as part of the Reliable Neural-Interface Technology (RE-NET) program and led by Professor Jack Judy.

Dr. Oxley announced in a 2018 TEDxSydney Talk[4] that the company, Synchron, would initiate clinical trials of the Stentrode device with the goal of assisting paralyzed patients to regain independence.

Just two years later, Oxley and Synchron published a first-in-human study on the device in the Journal of NeuroInterventional Surgery. The study showed the ability of two Australians with ALS to email, text, shop, and bank online using the Stentrode Device, and was conducted at Royal Melbourne Hospital. Earlier in 2020, the company had announced that it received Breakthrough Device status from the US Food and Drug Administration (FDA) for the Stentrode.[5]

Oxley's work has been published in major journals including Nature Biotechnology[6] and New England Journal of Medicine,[7] and he is the founder of three start-up companies: SmartStent (which was acquired by Synchron, Inc.[8]), VascuLab and Synchron.

COVID-19 research

edit

Oxley and his colleagues at Mount Sinai reported an increased incidence of stroke identified in patients under 50 years of age with COVID-19, which was published in New England Journal of Medicine in April 2020.[9]

Education

edit

After earning bachelor's degrees in medical science, medicine and surgery from the University of Monash in Melbourne Australia, Oxley earned doctorate degrees in philosophy and neuroscience from the University of Melbourne. His training included advanced MRI imaging analysis, hardware device (stent) development, and electrophysiological signal processing. Oxley completed residencies in both internal medicine and neurology, as well as a stroke fellowship. From 2015 – 2017, Oxley completed an endovascular neurosurgery fellowship at Mount Sinai Hospital in New York under Professor J. Mocco and Professor Alejandro Berenstein.

Scientific career

edit

Dr Oxley has published 100 internationally peer reviewed articles that have accumulated over 6500 citations, with 13 as first or last author and with an H Index of 20.[10]

Honors and awards

edit

In 2018, Oxley won the 2018 Global Australian Advance Award Winner,[11] an award given to celebrate international Australians who exhibit remarkable talent, exceptional vision and ambition, the UNESCO Netexplo award for Innovation,[12] and was a finalist for the Congress of Neurological Surgeons Innovator of the Year Award.[13]

  • 2020 Australian of the Year Award Finalist [14]
  • 2018 GQ Australia Innovator of the Year finalist
  • 2018 Advance Global Overall Australian of the Year Award[11]
  • 2018 Advance Global Australia Award for Life Sciences[15]
  • 2018 Congress of Neurological Surgeons (USA), 2018 Innovator of the Year
  • 2018 UNESCO Netexplo award for Innovation, Paris, France[12]
  • 2017 Chancellor's Prize for Excellence in a PhD Thesis, University of Melbourne
  • 2017 Dean's Award for Excellence in a PhD Thesis, University of Melbourne
  • 2017 International INDEX Design Awards Finalist, Stentrode, Copenhagen, Denmark
  • 2017 Graham Brown Best Publication Award, University of Melbourne
  • 2016 Premier's Award (Victoria) for Health and Medical Research (PhD) commendation[16]
  • 2016 International Brain Computer Interface Award Finalist[17]
  • 2016 SMART 100 companies
  • 2016 Nomination for University of Melbourne Chancellor's PhD Award
  • 2013 Warren Haynes Fellowship in Neurology
  • 2013 NHMRC Postgraduate Scholarship
  • 2013 Winner, MTGT Entrepreneurial Accelerator

References

edit
  1. ^ "Thomas Oxley at Mt. Sinai". www.mountsinai.org. Retrieved 27 June 2019.
  2. ^ "University of Melbourne Vascular Bionics Laboratory". medicine.unimelb.edu.au. 2 April 2019. Retrieved 27 June 2019.
  3. ^ "Thomas Oxley, University of Melbourne". findanexpert.unimelb.edu.au. Retrieved 27 June 2019.
  4. ^ "A Digital Spinal Cord that Streams Your Thoughts". YouTube. Retrieved 27 June 2019.
  5. ^ Hollis, Liz. "FDA Grants Breakthrough Designation to Synchron's Stentrode Brain Computer Interface". BioWorld. Retrieved 23 November 2020.
  6. ^ Oxley, Thomas (2016). "Minimally Invasive Endovascular Stent-Electrode Array for High-Fidelity, Chronic Recordings of Cortical Neural Activity". Nature Biotechnology. 34 (3): 320–7. doi:10.1038/nbt.3428. PMID 26854476. S2CID 205282364. Retrieved 27 June 2019.
  7. ^ Campbell, Bruce C.V.; Mitchell, Peter J.; Kleinig, Timothy J.; Dewey, Helen M.; Churilov, Leonid; Yassi, Nawaf; Yan, Bernard; Dowling, Richard J.; Parsons, Mark W.; Oxley, Thomas J.; Wu, Teddy Y.; Brooks, Mark; Simpson, Marion A.; Miteff, Ferdinand; Levi, Christopher R.; Krause, Martin; Harrington, Timothy J.; Faulder, Kenneth C.; Steinfort, Brendan S.; Priglinger, Miriam; Ang, Timothy; Scroop, Rebecca; Barber, P. Alan; McGuinness, Ben; Wijeratne, Tissa; Phan, Thanh G.; Chong, Winston; Chandra, Ronil V.; Bladin, Christopher F.; et al. (2015). "Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection". New England Journal of Medicine. 372 (11): 1009–1018. doi:10.1056/NEJMoa1414792. hdl:2292/27109. PMID 25671797. S2CID 4688893.
  8. ^ "Endovascular Start-Up Synchron, Inc. Appoints Neurovascular Veteran Martin Dieck as Chairman". businesswire.com. Business Wire. 21 April 2016. Retrieved 27 June 2019.
  9. ^ Oxley, Thomas (2020). "Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young". The New England Journal of Medicine. 382 (20): e60. doi:10.1056/NEJMc2009787. PMC 7207073. PMID 32343504.
  10. ^ "Thomas J Oxley". Google Scholar. Retrieved 2 December 2020.
  11. ^ a b "Dr. Thomas Oxley Announced as Overall Winner in 2018 Advance Awards". advance.org. Archived from the original on 27 June 2019. Retrieved 27 June 2019.
  12. ^ a b "Stentrode". netexplo.org. Netexplo Observatory. Retrieved 27 June 2019.
  13. ^ "Awards". cns.org. Congress of Neurological Surgeons. Retrieved 27 June 2019.
  14. ^ "VIC Nominee Australian of the Year 2021". Australian of the Year Awards. Australia Day. Archived from the original on 27 November 2020. Retrieved 1 December 2020.
  15. ^ "Dr. Thomas Oxley". advance.org. Retrieved 27 June 2019.
  16. ^ "Honouring Victoria's Brightest Medical Researchers". premier.vic.gov.au. Delivering. Retrieved 27 June 2019.
  17. ^ "The Winners of the Annual BCI Award 2016". blog.gtec.at. G Tec. Retrieved 27 June 2019.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Thomas_Oxley_(neurologist)&oldid=1227027318"